---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011797"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:05:13.299509+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx reports Q2 net loss of $48.6M and $50M offering led by Sanofi

## Summary
- Net loss $48.6M ($0.76/share) vs $29.6M ($0.53) in Q2 2023; service revenue $0.3M, no license revenue.
- Offering of 12.5M shares at $4.00 each for $50M gross proceeds; led by Sanofi ($30M) with Perceptive Advisors.
- Cash and equivalents $100.0M as of June 30, 2024; believes funded into Q2 2026 with $285M potential J&J milestones.
- Phase 2 AQUAx2 for xerostomia enrolling; FDA aligned on pivotal trial design. AAV-GAD for Parkinson's results expected Q4 2024.
- UK ILAP designation for AAV-AIPL1 in LCA4; all 11 treated blind children gained visual acuity. Riboswitch platform data later 2024.

## SEC filing metadata
- accession: 0001558370-24-011797
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837024011797/0001558370-24-011797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837024011797/mgtx-20240812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011797
- JSON: https://secwatch.observer/filing/0001558370-24-011797.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011797.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.